{"id":"glucagen-hypokit","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperglycemia (rebound)"}]},"_chembl":{"chemblId":"CHEMBL5314342","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucagon is a hormone that binds to glucagon receptors on hepatic cells, stimulating glycogenolysis and gluconeogenesis to increase blood glucose concentration. The HypoKit formulation aims to provide a ready-to-use, user-friendly delivery system for emergency glucagon administration in hypoglycemic episodes, particularly in diabetes patients.","oneSentence":"GlucaGen HypoKit is a glucagon formulation designed to rapidly raise blood glucose levels in patients experiencing severe hypoglycemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:01.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe hypoglycemia in patients with diabetes"}]},"trialDetails":[{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT03667053","phase":"PHASE3","title":"Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2018-09-28","conditions":"Hypoglycemia","enrollment":42},{"nctId":"NCT03378635","phase":"PHASE3","title":"A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2017-12-07","conditions":"Hypoglycemia, Diabetes Mellitus, Type 1","enrollment":170},{"nctId":"NCT03216226","phase":"PHASE3","title":"A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2017-06-28","conditions":"Hypoglycemia, Diabetes Mellitus, Type 1","enrollment":112},{"nctId":"NCT03738865","phase":"PHASE3","title":"G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Xeris Pharmaceuticals","startDate":"2018-09-27","conditions":"Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia","enrollment":132},{"nctId":"NCT01959334","phase":"PHASE3","title":"Evaluate the Immunogenicity of a Novel Glucagon Formulation","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-09","conditions":"Drug-specific Antibodies, Diabetes Mellitus","enrollment":75},{"nctId":"NCT03176524","phase":"PHASE1","title":"A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM","status":"COMPLETED","sponsor":"Adocia","startDate":"2017-06-06","conditions":"Type 1 Diabetes Mellitus","enrollment":27},{"nctId":"NCT02635243","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia","status":"WITHDRAWN","sponsor":"Sanofi","startDate":"2016-04","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT02625636","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02240043","phase":"NA","title":"Growth Hormone Evaluation in the Elderly People","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2011-09","conditions":"Aging","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GlucaGen® HypoKit®","genericName":"GlucaGen® HypoKit®","companyName":"Adocia","companyId":"adocia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GlucaGen HypoKit is a glucagon formulation designed to rapidly raise blood glucose levels in patients experiencing severe hypoglycemia. Used for Severe hypoglycemia in patients with diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}